Vanderbilt-Ingram Cancer Center, Nashville, TN.
Division of Hematology and Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, OR.
JCO Oncol Pract. 2021 Oct;17(10):607-614. doi: 10.1200/OP.20.00701. Epub 2021 Feb 3.
Despite efforts to enhance enrollment and the merger of national cooperative groups, < 5% of patients with cancer will enroll into a clinical trial. Additionally, clinical trials are affected by a lack of diversity inclusive of minority patients, rural residents, or low-income individuals. COVID-19 further exacerbated known barriers of reduced physician-patient interaction, physician availability, trial activation and enrollment, financial resources, and capacity for conducting research. Based on the cumulative insight of academic and community clinical researchers, we have created a white paper identifying existing challenges in clinical trial conduct and have provided specific recommendations of sustainable modifications to improve efficiency in the activation and conduct of clinical trials with an overarching goal of providing improved access and care to our patients with cancer.
尽管已经努力增加参与人数并合并国家合作团体,但仍只有不到 5%的癌症患者参与临床试验。此外,临床试验还受到多样性不足的影响,包括少数民族患者、农村居民或低收入人群。COVID-19 进一步加剧了减少医患互动、医生可及性、试验启动和参与、财务资源以及进行研究的能力等已知障碍。基于学术和社区临床研究人员的综合见解,我们创建了一份白皮书,确定了临床试验实施中存在的挑战,并提出了可持续改进的具体建议,以提高临床试验的启动和实施效率,最终目标是为癌症患者提供更好的治疗机会和护理。